Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Glioblastoma Institute
Tumor Boards
Colleague Insights
Living Resources
Conferences
Video Expert Opinion
Sign in
Join now
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
Roxana Dronca MD
Roxana S. Dronca MD Advisory Board
See All Experts
featured
Published in Oncology and
1 other channel

Expert Opinion / Interview · December 03, 2019

Second Interim Analysis From a Phase III Trial on Concurrent and Adjuvant Temozolomide for Anaplastic Glioma Without 1p/19q Codeletion

Farzanna Haffizulla MD, FACP, FAMWA
Roger Stupp MD
Interview with
Roger Stupp MD

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Roger Stupp MD

Further Reading

Related Videos